Babiker HM, Riaz IB, Husnain M, Borad MJ. Oncolytic virotherapy including Rigvir and standard therapies in
malignant melanoma. Oncolytic Virother. 2017;6:11-18.
Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug
Discov. 2015;14(9):642-662.
Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci.
2016;107(10):1373-1379.
Li X, Wang P, Li H, et al. The efficacy of oncolytic adenovirus is mediated by T-cell responses against
virus and tumor in Syrian hamster model. Clin Cancer Res. 2017;23(1):239-249.
Tuve S, Liu Y, Tragoolpua K, et al. In situ adenovirus vaccination engages T effector cells against cancer.
Vaccine. 2009;27(31):4225-4239.
Kim HS, Kim-Schulze S, Kim DW, Kaufman HL. Host lymphodepletion enhances the therapeutic activity of an
oncolytic vaccinia virus expressing 4-1BB ligand. Cancer Res. 2009;69(21):8516-8525.
Chen CY, Wang PY, Hutzen B, et al. Cooperation of oncolytic herpes virotherapy and PD-1 blockade in murine
rhabdomyosarcoma models. Sci Rep. 2017;7(1):2396. doi:10.1038/s41598-017-02503-8.